Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data PSYENCE BIOMEDICAL LTD. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Research and development
1.61
0.95
0.34
Interest expense
0.05
Interest income
0
-0
Pre-tax income
-3.23
-2.75
-3.66
Net income
-3.21
-51.2
1.01
EPS, basic
-394.06
-4,674.00
5.24
EPS, diluted
-394.06
-4,674.00
5.24
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
1.33
0.73
6.14
Total current assets
1.59
1.13
6.56
Property, plant and equipment
0.01
0.01
Total assets
1.59
1.13
7.32
Accounts payable
1.79
0.76
Total liabilities
1.79
12.1
0.59
Total debt
10.4
Retained earnings
-6.3
-57.5
-56.4
Shareholders' equity
-0.2
Total equity
-0.2
-11
6.72
Total liabilities and equity
1.59
1.13
7.32
Cash flow statement
FY2024
FY2024
FY2025
Net income
-3.21
-51.2
1.01
Cash from operations
-1.59
-2.95
-3.73
Capital expenditures
-0.01
-0.01
Cash from investing
-0.01
-0.02
Debt issued
2.5
1
Debt repaid
-0.15
Stock issued
1.74
Cash from financing
1.17
2.35
9.15
Net change in cash
-0.42
-0.6
5.4
Free cash flow
-2.95
-3.74
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $5.56 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
24.0%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
546.2%
Total assets vs the same period a year earlier. Only from a positive base.
Balance sheet health
Metric
Value
How it is calculated
Liabilities / assets
8.1%
Total liabilities / total assets.
Efficiency
Metric
Value
How it is calculated
FCF conversion
-370.0%
Free cash flow / net income, when net income is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
$5.24
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
$5.24
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$21.2M
Share price x shares outstanding.
Enterprise value
$15.1M
Market cap + total debt - cash - short-term investments.
P/E
21.0x
Market cap / net income. Only when net income is positive.
FCF yield
-17.7%
Free cash flow / market cap.
Earnings yield
4.8%
Net income / market cap (the inverse of P/E).
Was PSYENCE BIOMEDICAL LTD. profitable in fiscal 2025?
Yes. Net income was $1.0M, a net margin of -.
How much free cash flow did PSYENCE BIOMEDICAL LTD. generate in fiscal 2025?
Cash from operations of $3.7M minus capital expenditures of $9.9K left free cash flow of -$3.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.